Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

November 23, 2015

Primary Completion Date

January 23, 2017

Study Completion Date

April 13, 2017

Conditions
Stable Angina
Interventions
DRUG

Erenumab

A single dose of erenumab 140 mg infused over approximately 60 minutes.

DRUG

Placebo

A single dose of a matching volume of placebo infused over approximately 60 minutes.

Trial Locations (33)

1023

Research Site, Grafton, Auckland

1038

Research Site, Riga

1211

Research Site, Geneva

1407

Research Site, Sofia

1431

Research Site, Sofia

1606

Research Site, Sofia

6300

Research Site, Haskovo

7505

Research Site, Parow

8011

Research Site, Christchurch

30342

Research Site, Atlanta

32216

Research Site, Jacksonville

33125

Research Site, Miami

38305

Research Site, Jackson

60616

Research Site, Chicago

76301

Research Site, Wichita Falls

78130

Research Site, New Braunfels

89128

Research Site, Las Vegas

300244

Research Site, Timișoara

250 01

Research Site, Brandýs nad Labem

430 02

Research Site, Chomutov

140 21

Research Site, Prague

261 01

Research Site, Pribram VIII

31-202

Research Site, Krakow

91-347

Research Site, Lodz

41-800

Research Site, Zabrze

085 01

Research Site, Bardejov

977 42

Research Site, Brezno

984 01

Research Site, Lučenec

921 01

Research Site, Piešťany

080 01

Research Site, Prešov

089 01

Research Site, Svidník

911 01

Research Site, Trenčín

010 01

Research Site, Žilina

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY